Symbols / RGNT $9.07 +504.33% Regentis Biomaterials Ltd.

Healthcare • Medical Instruments & Supplies • Israel • ASE
RGNT Chart
O: — H: — L: — C: — V: —
SMA 20: SMA 50: SMA 200:
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Instruments & Supplies
CEO Dr. Ehud Geller Ph.D.
Exch · Country ASE · Israel
Market Cap 46.95M
Enterprise Value 1.59M
Income -13.69M
Sales
FCF (ttm) 3.03M
Book/sh 0.92
Cash/sh 1.42
Employees
Insider 10d
IPO Dec 04, 2025
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E
Forward P/E
PEG
P/S
P/B 9.90
P/C
EV/EBITDA
EV/Sales
Quick Ratio 2.65
Current Ratio 2.65
Debt/Eq 25.23
LT Debt/Eq
EPS (ttm) -24.16
EPS next Y
EPS Growth
Revenue Growth
EPS Gr Q/Q
Rev Gr Q/Q
Earnings (next)
Earnings (prior)
ROA -107.53%
ROE
ROIC
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 5.18M
Shs Float 2.82M
Insider Own 19.05%
Instit Own 28.49%
Short Float 0.79%
Short Ratio 0.88
Short Interest 25.58K
52W High 15.50
vs 52W High -41.52%
52W Low 1.23
vs 52W Low 635.80%
Beta
Impl. Vol.
Rel Volume 88.28
Avg Volume 2.02M
Volume 178.16M
Target (mean) $10.00
Tgt Median $10.00
Tgt Low $10.00
Tgt High $10.00
# Analysts 1
Recom None
Prev Close $1.50
Price $9.06
Change 504.33%

Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus Mean price target
2. Current target Latest analyst target
3. DCF / Fair value Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$9.40
Low
$10.00
High
$10.00
Mean
$10.00
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
8.62
+1024.79%
-0.93
-148.27%
1.93
+37.24%
1.41
Research And Development
0.33
+120.13%
-1.64
-303.97%
0.81
-16.99%
0.97
Selling General And Administration
8.29
+1064.04%
0.71
-36.71%
1.12
+158.03%
0.44
General And Administrative Expense
8.29
+1064.04%
0.71
-36.71%
1.12
+158.03%
0.44
Salaries And Wages
7.55
0.00
0.00
Other Gand A
0.67
+3.73%
0.64
-39.28%
1.06
+200.85%
0.35
Total Expenses
8.62
+1024.79%
-0.93
-148.27%
1.93
+37.24%
1.41
Operating Income
-8.62
-1024.79%
0.93
+148.27%
-1.93
-37.24%
-1.41
Total Operating Income As Reported
-6.97
-847.64%
0.93
+148.27%
-1.93
-37.24%
-1.41
EBITDA
-13.32
-367.98%
4.97
+225.59%
-3.96
-173.22%
-1.45
Normalized EBITDA
-13.55
-407.16%
4.41
+211.64%
-3.95
-118.88%
-1.81
EBIT
-13.32
-367.98%
4.97
+225.59%
-3.96
-173.22%
-1.45
Total Unusual Items
0.23
-58.68%
0.56
+9416.67%
-0.01
-101.68%
0.36
Total Unusual Items Excluding Goodwill
0.23
-58.68%
0.56
+9416.67%
-0.01
-101.68%
0.36
Net Income
-13.65
-384.27%
4.80
+216.19%
-4.13
-185.16%
-1.45
Pretax Income
-13.65
-384.27%
4.80
+216.19%
-4.13
-185.16%
-1.45
Net Non Operating Interest Income Expense
-5.26
-258.91%
3.31
+250.80%
-2.19
-450.13%
-0.40
Interest Expense Non Operating
0.32
+89.47%
0.17
-1.16%
0.17
0.00
Net Interest Income
-5.26
-258.91%
3.31
+250.80%
-2.19
-450.13%
-0.40
Interest Expense
0.32
+89.47%
0.17
-1.16%
0.17
0.00
Other Income Expense
0.23
-58.68%
0.56
+9416.67%
-0.01
-101.68%
0.36
Other Non Operating Income Expenses
3.48
+272.51%
-2.02
-408.56%
-0.40
Gain On Sale Of Security
0.23
-58.68%
0.56
+9416.67%
-0.01
-101.68%
0.36
Tax Rate For Calcs
0.00
-100.00%
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
-100.00%
0.13
0.00
0.00
Net Income Including Noncontrolling Interests
-13.65
-384.27%
4.80
+216.19%
-4.13
-185.16%
-1.45
Net Income From Continuing Operation Net Minority Interest
-13.65
-384.27%
4.80
+216.19%
-4.13
-185.16%
-1.45
Net Income From Continuing And Discontinued Operation
-13.65
-384.27%
4.80
+216.19%
-4.13
-185.16%
-1.45
Net Income Continuous Operations
-13.65
-384.27%
4.80
+216.19%
-4.13
-185.16%
-1.45
Normalized Income
-13.88
-417.56%
4.37
+205.93%
-4.13
-128.46%
-1.81
Net Income Common Stockholders
-13.69
-388.07%
4.75
+213.71%
-4.18
-179.23%
-1.50
Otherunder Preferred Stock Dividend
0.04
-8.33%
0.05
+0.00%
0.05
+0.00%
0.05
Diluted EPS
0.92
+213.71%
-0.81
-179.23%
-0.29
Basic EPS
0.92
+213.71%
-0.81
-179.23%
-0.29
Basic Average Shares
5.18
+0.00%
5.18
+0.00%
5.18
Diluted Average Shares
5.18
+0.00%
5.18
+0.00%
5.18
Diluted NI Availto Com Stockholders
-13.69
-388.07%
4.75
+213.71%
-4.18
-179.23%
-1.50
Rent And Landing Fees
0.07
-2.90%
0.07
+4.55%
0.07
-21.43%
0.08
Rent Expense Supplemental
0.07
-2.90%
0.07
+4.55%
0.07
-21.43%
0.08
Total Other Finance Cost
4.94
+241.80%
-3.48
-272.16%
2.02
+406.77%
0.40
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
7.62
+1480.50%
0.48
+33.89%
0.36
-79.03%
1.72
Current Assets
7.62
+1480.50%
0.48
+33.89%
0.36
-79.03%
1.72
Cash Cash Equivalents And Short Term Investments
7.38
+3121.83%
0.23
-33.62%
0.34
-72.18%
1.24
Cash And Cash Equivalents
7.38
+3121.83%
0.23
-33.62%
0.34
-72.18%
1.24
Receivables
0.23
+215.07%
0.07
+812.50%
0.01
-69.23%
0.03
Other Receivables
0.23
+215.07%
0.07
+812.50%
0.01
-69.23%
0.03
Prepaid Assets
0.01
-94.44%
0.18
+2471.43%
0.01
-98.45%
0.45
Total Non Current Assets
0.00
0.00
0.00
0.00
Total Liabilities Net Minority Interest
2.87
-93.09%
41.59
-10.11%
46.27
+5.68%
43.78
Current Liabilities
2.87
-55.70%
6.49
+106.69%
3.14
+20.31%
2.61
Payables And Accrued Expenses
1.66
+20.30%
1.38
+58.14%
0.87
+39.30%
0.63
Payables
0.27
+5.56%
0.25
-28.81%
0.35
+70.19%
0.21
Accounts Payable
0.27
+5.56%
0.25
-28.61%
0.35
+71.36%
0.21
Other Payable
0.00
-50.00%
0.00
Current Accrued Expenses
1.39
+23.60%
1.13
+117.57%
0.52
+23.92%
0.42
Pensionand Other Post Retirement Benefit Plans Current
0.02
+350.00%
0.00
+33.33%
0.00
+50.00%
0.00
Current Debt And Capital Lease Obligation
1.20
-75.79%
4.95
+2254.76%
0.21
Current Debt
1.20
-75.79%
4.95
+2254.76%
0.21
Other Current Borrowings
1.20
-75.79%
4.95
+2254.76%
0.21
Current Deferred Liabilities
0.00
-100.00%
2.05
+3.69%
1.98
Current Deferred Revenue
0.00
-100.00%
2.05
+3.69%
1.98
Other Current Liabilities
0.16
Total Non Current Liabilities Net Minority Interest
0.00
-100.00%
35.10
-18.62%
43.13
+4.75%
41.17
Long Term Debt And Capital Lease Obligation
7.41
+14.42%
6.47
Long Term Debt
7.41
+14.42%
6.47
Preferred Securities Outside Stock Equity
0.00
-100.00%
35.10
+0.00%
35.10
+3.19%
34.01
Stockholders Equity
4.74
+111.54%
-41.10
+10.46%
-45.91
-9.14%
-42.06
Common Stock Equity
4.74
+111.54%
-41.10
+10.46%
-45.91
-9.14%
-42.06
Capital Stock
0.00
0.00
0.00
0.00
Common Stock
0.00
0.00
0.00
0.00
Share Issued
5.18
+0.00%
5.18
+5.07%
4.93
+0.00%
4.93
Ordinary Shares Number
5.18
+0.00%
5.18
+5.07%
4.93
+0.00%
4.93
Additional Paid In Capital
60.54
+5709.79%
1.04
+0.00%
1.04
+38.20%
0.75
Retained Earnings
-55.79
-32.38%
-42.15
+10.23%
-46.95
-9.65%
-42.81
Total Equity Gross Minority Interest
4.74
+111.54%
-41.10
+10.46%
-45.91
-9.14%
-42.06
Total Capitalization
4.74
+111.54%
-41.10
-6.76%
-38.50
-8.18%
-35.59
Working Capital
4.74
+178.99%
-6.01
-116.12%
-2.78
-211.55%
-0.89
Invested Capital
5.94
+116.43%
-36.16
+5.57%
-38.29
-7.59%
-35.59
Total Debt
1.20
-75.79%
4.95
-35.06%
7.62
+17.66%
6.47
Net Debt
4.72
-35.13%
7.27
+38.95%
5.23
Net Tangible Assets
4.74
+111.54%
-41.10
+10.46%
-45.91
-9.14%
-42.06
Tangible Book Value
4.74
+111.54%
-41.10
+10.46%
-45.91
-9.14%
-42.06
Derivative Product Liabilities
0.00
-100.00%
0.62
-9.05%
0.69
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-1.38
-114.51%
-0.64
+47.46%
-1.22
+18.88%
-1.50
Cash Flow From Continuing Operating Activities
-1.38
-114.51%
-0.64
+47.46%
-1.22
+18.88%
-1.50
Net Income From Continuing Operations
-13.65
-384.27%
4.80
+216.19%
-4.13
-185.16%
-1.45
Other Non Cash Items
5.26
+258.82%
-3.31
-251.09%
2.19
+452.14%
0.40
Operating Gains Losses
6.88
+1396.05%
-0.53
-4927.27%
0.01
+103.34%
-0.33
Gain Loss On Investment Securities
-0.16
+65.44%
-0.46
-646.77%
-0.06
+38.00%
-0.10
Net Foreign Currency Exchange Gain Loss
0.00
+100.00%
-0.07
-193.15%
0.07
+131.88%
-0.23
Change In Working Capital
0.13
+108.19%
-1.60
-325.53%
0.71
+676.42%
-0.12
Change In Payables And Accrued Expense
0.29
+121.60%
-1.36
-651.01%
0.25
+1552.94%
-0.02
Change In Payable
0.29
+121.60%
-1.36
-651.01%
0.25
+1552.94%
-0.02
Change In Account Payable
0.01
+113.86%
-0.10
-168.71%
0.15
+244.12%
-0.10
Change In Other Current Assets
-0.16
+31.51%
-0.24
-151.52%
0.46
+535.85%
-0.11
Financing Cash Flow
8.52
+1523.62%
0.53
+61.54%
0.33
0.00
Cash Flow From Continuing Financing Activities
8.52
+1523.62%
0.53
+61.54%
0.33
0.00
Net Issuance Payments Of Debt
0.30
-42.86%
0.53
+61.54%
0.33
0.00
Issuance Of Debt
0.30
-64.71%
0.85
+161.54%
0.33
0.00
Repayment Of Debt
0.00
+100.00%
-0.33
0.00
Long Term Debt Issuance
0.00
-100.00%
0.45
0.00
0.00
Net Long Term Debt Issuance
0.00
-100.00%
0.45
0.00
0.00
Short Term Debt Issuance
0.30
-25.00%
0.40
+23.08%
0.33
0.00
Short Term Debt Payments
0.00
+100.00%
-0.33
0.00
Net Short Term Debt Issuance
0.30
+300.00%
0.07
-76.92%
0.33
0.00
Net Common Stock Issuance
8.22
0.00
0.00
Changes In Cash
7.15
+6262.93%
-0.12
+87.04%
-0.90
+40.49%
-1.50
Beginning Cash Position
0.23
-33.62%
0.34
-72.18%
1.24
-54.81%
2.74
End Cash Position
7.38
+3121.83%
0.23
-33.62%
0.34
-72.18%
1.24
Free Cash Flow
-1.38
-114.51%
-0.64
+47.46%
-1.22
+18.88%
-1.50
Common Stock Issuance
8.22
0.00
0.00
Earnings Losses From Equity Investments
7.04
0.00
Issuance Of Capital Stock
8.22
0.00
0.00
SEC Filings

No SEC filings found for this symbol (may be non-US or ticker not in SEC index).

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category